What is the difference between BPC-157 and TB-500?

BPC-157: BPC-157 is a synthetic pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a 15-amino-acid fragment of body protection compound (BPC), a protein isolated from human gastric juice. It is research-... TB-500: TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to amino acids 17–23 of thymosin β4, the actin-binding region of the native 43-residue protein. Despite widespread vendor lab...

BPC-157 vs TB-500

Q: Can you stack BPC-157 and TB-500?

BPC-157 (recovery) and TB-500 (recovery) are in the same category and may have overlapping mechanisms — researchers should review both profiles carefully before combining. Consult a licensed provider before combining any compounds.

Head-to-head comparison of BPC-157 and TB-500 — mechanism, dosing, side effects, legal status, and pricing.

BPC-157

BPC-157 is a synthetic pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a 15-amino-acid fragment of body protection compound (BPC), a protein isolated from human gastric juice. It is research-only, not approved by the FDA or any major regulator for human use, and almost all published evidence comes from rodent models.

Profile Prices Calculator

TB-500

TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to amino acids 17–23 of thymosin β4, the actin-binding region of the native 43-residue protein. Despite widespread vendor labeling, TB-500 is NOT identical to full-length thymosin β4 (Tβ4); it is a short fragment containing the central actin-binding motif. It is sold as a research chemical and is not FDA-approved for any human indication.

Profile Prices Calculator

BPC-157

TB-500

Category

Recovery

Legal Status

Category 1 — Legally Compoundable

Mechanism

Preclinical studies suggest BPC-157 promotes angiogenesis and granulation tissue formation, with reported upregulation of VEGFR2 signaling and activation of the FAK-paxillin pathway in tendon fibroblasts. It has also been reported to modulate the nitric oxide system and interact with dopaminergic and serotonergic pathways along the gut-brain axis. A precise receptor target has not been established.

Native thymosin β4 is the principal G-actin–sequestering peptide in mammalian cells, regulating cytoskeletal dynamics and thereby cell migration. In preclinical models Tβ4 promotes endothelial and epithelial cell migration, angiogenesis, and survival signaling (including activation of an ILK/Akt complex in cardiomyocytes), and downregulates pro-inflammatory cytokines during tissue repair. The TB-500 fragment retains the actin-binding motif, but whether the short peptide fully reproduces Tβ4's in vivo activity in humans has not been established.

Dose Range

250–500 mcg (community-reported, not clinically validated)

Not clinically validated; grey-market protocols cite ~2–2.5 mg

Route

SubQ or Oral

SubQ or IM (research use only)

Frequency

1–2 times daily

Vendor-suggested 2x/week loading for 4–6 weeks, then weekly maintenance

Dosing Notes

No clinically validated human dose exists. Vendor and community protocols commonly cite 250–500 mcg SubQ once or twice daily, often near the site of injury, with oral dosing used for GI-related goals. Cycles of roughly 4–6 weeks are typical in user reports. Pharmacokinetics and long-term safety in humans are not well characterized.

No clinically validated human injection dose exists for the short TB-500 peptide. All dosing figures circulating online are derived from vendor and forum protocols, not controlled human trials. The only human clinical data for any Tβ4-derived product involve topical ophthalmic full-length Tβ4 (RGN-259), not injected TB-500.

Side Effects

Nausea (especially oral)
Dizziness or lightheadedness
Injection site irritation
Headache
Note: the human side-effect profile is not well characterized in peer-reviewed literature

Injection site reactions
Headache and lethargy reported anecdotally
Theoretical risk of promoting growth of occult tumors via angiogenesis and cell migration (not established in humans)
Unknown long-term safety profile in humans

Contraindications

Active cancer or history of cancer (theoretical concern due to pro-angiogenic activity in preclinical models)
Pregnancy or breastfeeding (no safety data)
Concurrent immunosuppressant therapy without medical supervision

Active or suspected malignancy (Tβ4 promotes angiogenesis and cell migration)
Pregnancy and breastfeeding (no human safety data)
Banned by WADA and most sports organizations — prohibited in competitive athletes
Not for therapeutic use; research chemical status only

BPC-157 Research Summary

Extensive rodent data from the Sikiric group and others report accelerated healing of tendon, ligament, muscle, and gastrointestinal injury, plus cytoprotective effects in models of NSAID and alcohol damage. Published human clinical evidence is limited; an early oral formulation (PL 14736) was explored for inflammatory bowel disease but has not progressed to approval. No peer-reviewed trial validates the injectable doses commonly used on the grey market.

Key references

TB-500 Research Summary

Animal studies of full-length Tβ4 show accelerated dermal wound reepithelialization, increased angiogenesis, improved cardiac function after ischemic injury, and corneal healing. The short Ac-LKKTETQ peptide sold as TB-500 was characterized analytically in the anti-doping literature as a substance with suspected doping potential; controlled human efficacy trials of injected TB-500 do not exist. Full-length synthetic Tβ4 (RGN-259, RegeneRx/HLB Therapeutics) has been evaluated in Phase II/III ophthalmic trials for dry eye disease and neurotrophic keratopathy with mixed results (one Phase III NK trial met healing endpoints, a later European Phase III missed its primary endpoint).

Key references

Can you stack BPC-157 and TB-500?

BPC-157 and TB-500 are both in the Recovery category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.

Other comparisons

Semaglutide vs Tirzepatide Ipamorelin vs CJC-1295 CJC-1295 vs Sermorelin Semaglutide vs Liraglutide Selank vs Semax BPC-157 vs GHK-Cu MK-677 vs Ipamorelin Semaglutide vs Retatrutide

This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.

BPC-157

TB-500

TB-500 Research Summary

Can you stack BPC-157 and TB-500?